Back to search

Switzerland· 65050003

Granisetron Fresenius

A granisetron product containing granisetronum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC A04AA02

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedGranisetron FreseniusATCA04AA02REGISTER NO.65050003PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Granisetron is registered in 18 of 19 countries.

Countries holding a registration under ATC A04AA02 (granisetron), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 10 of them publish a price we can compare per daily dose

Granisetron · ATC A04AA02

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of granisetron costs, country by country.

Normalised to the WHO defined daily dose (2 mg), the median price runs from $10.02 in Italy to $29.01 in Switzerland — a ×2.9 gap.

  • Switzerland: $29.01 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Granisetron · price per daily dose (2 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$29.01
  • FR France$11.60
  • IT Italy$10.02
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
granisetronum
Manufacturer
—
Country
Switzerland (CH)
ATC code
A04AA02
ATC class
Granisetron
Defined daily dose
2 mg, O
Swissmedic category
B
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680650500032
    5x 3 ml
    CHF 88.9

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

564 interactions on record for granisetron.

Graded by severity as the source publishes them — 139 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Granisetron · interactions on record

564 records

  • 139 severe
  • 244 moderate
  • 9 minor
  • 172 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • FenfluramineA08AA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Granisetron in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All granisetron products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Granisetron Actavis, Kytril
  • Belgium · Granisetron Fresenius Kabi, Kytril
  • Bulgaria · Расетрон
  • Czechia · Granegis, Granisetron Kabi
  • Germany · Grani, Granisetron Baxter
  • Denmark · Granisetron Hameln, Granisetron Stada
  • Estonia · Kytril
  • Spain · Granisetrón Altan, Granisetrón Aurovitas Spain
  • Finland · Gazoron, Granisetron Baxter
  • France · Kytril
  • United Kingdom (Northern Ireland) · Granisetron, Granisetron Dawa
  • Greece · Granitron, Viatrinil 1mg/Ml
  • Croatia · Granizetron Kabi
  • Hungary · Granegis, Granigen
  • Ireland · Kytril
  • Iceland · Grandise, Granem
  • Italy · Grandise, Granem
  • Liechtenstein · Sancuso
  • Malta · Granisetron Sigillata
  • Netherlands · Granisetron Baxter, Granisetron Fresenius Kabi
  • Norway · Sancuso
  • Portugal · Granisetron Orchid Europe, Granissetrom Aurovitas
  • Romania · Granisetron Kabi, Granisetron Labormed
  • Sweden · Granisetron Fresenius Kabi, Granisetron Hameln
  • Slovenia · Granisetron Lek, Kytril
  • Slovakia · Emegar, Granegis

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c4170a40-84e2-47a0-92f7-b89a02315b85
GET /v1/drugs/c4170a40-84e2-47a0-92f7-b89a02315b85?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "granisetronum 3 mg",
  "valid_from": "2015-01-01",
  "limitations": "[{\"description\":\"Stark emetogene Chemotherapie.\",\"costApproval\":null,\"indication\":null,\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2015-01-01\",\"validTo\":null}]",
  "galenic_form": "Inf Konz 3 mg/3ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2015-01-01",
  "self_retention_pct": 10
}

See everything about granisetron.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.